- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04169932
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- The First Affiliated Hospital with Nanjing Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Patients with CD20+ relapsed or refractory B cell Non-Hodgkin lymphoma, which includes but not limited to diffuse large B cell lymphoma (DLBCL), follicular lymphoma, transformed follicular lymphoma, marginal-zone lymphoma, mantle-cell lymphoma, small B-cell lymphoma, are eligible for inclusion in this study must meet one of the following criteria:
- Relapsed or refractory as defined by not achieving a PR after a second-line drug therapy such as CD20 monoclonal antibodies, or achieving a PR but the disease has progressed, or chieving a CR but the disease has relapsed.
- Relapse after autologous stem cell transplantation (SCT) within 1 year.
- 2. Adult subjects between 18 and 70 years of age, inclusive.
- 3. Life expectancy > 3 months.
- 4. ECOG score between 0 and 1.
5. Liver, Renal, Heart and Lungs function defined as:
- Creatininec≤1.5 ULN;
- ALT/AST ≤2.5 ULN;
- Total Bilirubin≤1.5×ULN;
- Pulse oxygenation≥92%;
- Left Ventricular Shortening Fraction (LVSF)≥50%;
- Echocardiogram (ECHO) shows no obvious pericardial effusion.
- 6. According to Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma, the lesions must meet the minimum size requirement of being >15 mm in longest diameter (LDi).
- 7. Subjects could comprehend the clinical study and able to provide written consent at the time of consent or assent.
Exclusion Criteria:
- 1. Pregnant or lactating women, or women with pregnancy plans within 6 months.
- 2. HBsAg or the titer of HBV was not in the range of normal reference value; positive for presence of HCV antibody or HCV RNA in peripheral blood; positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 or HIV-2).
- 3. Severe heart disease: include but not limited to Unstable angina pectoris, myocardial infarction (within 6 months before screening), Congestive heart failure (New York Heart Association [NYHA] Classification ≥ III).
- 4. Previously received other CART therapy or transgenic cell therapy.
- 5. The subjects participated in clinical trials within 6 months before screening.
- 6. Subjects who were receiving systemic steroid therapy and determined by the researchers to require long-term use of systemic steroid therapy except for inhalation or local use before screening.
- 7. Subjects who had more than 2 years of autoimmune disease history (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) that caused organ damage or subjects who needed to take systemic immunosuppressants;
- 8. Any unstable systemic disease, including but not limited to, liver, kidney or metabolic diseases requiring drug treatment.
- 9. Autologous transplantation or allotransplantation was performed within 6 months after admission.
- 10. Evidence or history of central nervous system involvement in lymphoma.
- 11. Subjects with active bleeding caused by the involvement of the original lesion in the digestive tract.
- 12. Subjects with active infectious diseases who received systematic antibiotic treatment within 2 weeks of admission.
- 13. Other subjects judged by the researchers to be unsuitable for admission to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CD20 CAR-T
|
The maximum dose was determined according to the dose escalation test.
Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course.
The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 ^ 6 cells/kg,2 × 10 ^ 6 cells/kg,4 × 10 ^ 6 cells/kg,8 × 10 ^ 6 cells/kg).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Adverse events (AEs)
Time Frame: 4 weeks
|
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
|
4 weeks
|
Expression of CD20 CART cells
Time Frame: 2 years
|
Expression of CD20 CART cells detected by flow cytometry in blood and bone marrow
|
2 years
|
Detection of CD20 CART cells
Time Frame: 2 years
|
Detection of CD20 CART cells in blood, bone marrow by Quantitative Polymerase Chain Reaction (q-PCR).
|
2 years
|
Graft Activity Endpoint Detection
Time Frame: 2 years
|
The vector copy number (VCN) of the exogenous CAR vector in the blood and bone marrow.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall remission rate (ORR)
Time Frame: 2 years
|
2 years
|
Complete Remission (CR)
Time Frame: 2 years
|
2 years
|
Partial Remission (PR)
Time Frame: 2 years
|
2 years
|
To evaluate the duration of remission (DOR)
Time Frame: 2 years
|
2 years
|
To evaluate the Progression-free survival (PFS)
Time Frame: 2 years
|
2 years
|
To evaluate the Overall survival (OS)
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20191023V1.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin Lymphoma
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Clinical Trials on CD20 CAR-T
-
Southwest Hospital, ChinaUnknown
-
Miltenyi Biomedicine GmbHDLR German Aerospace CenterRecruiting
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Miltenyi Biomedicine GmbHActive, not recruitingNon-Hodgkin's Lymphoma | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | B-cell Lymphoma RecurrentGermany
-
Xin WangUnknownRelapsed or Refractory B-cell LymphomasChina
-
He HuangYake Biotechnology Ltd.RecruitingRelapsed and Refractory | Lymphoid Hematological MalignanciesChina
-
Shanghai Longyao Biotechnology Inc., Ltd.Xuzhou Medical University; Shanghai Jiao Tong University School of MedicineUnknownRecurrent or Refractory B Cell MalignancyChina
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingLymphoma | Multiple Myeloma | Acute Lymphoblastic LeukemiaChina
-
Shanghai Tongji Hospital, Tongji University School...Cellular Biomedicine Group Ltd.CompletedB Cell LymphomaChina
-
Beijing Doing Biomedical Co., Ltd.Not yet recruitingLymphoma | LeukemiaChina